Ischaemic heart disease

CANTOS substudy shows major role for inflammation

Large reductions in hsCRP appeared to foretell improved outcomes. An important CANTOS trial substudy bolsters evidence that inflammation plays an independent role in cardiovascular disease (CVD) and may point toward a new targeted approach to treatment of CVD and perhaps even more profoundly impact cancer treatment. Canakinumab is a monoclonal antibody that targets IL-1ß and ...

Already a member?

Login to keep reading.

© 2021 the limbic